CPX-351 Plus Enasidenib for Relapsed Acute Myelogenous Leukemia Characterized by the IDH2 Mutation
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Enasidenib (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 26 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 26 Sep 2023 Status changed from suspended to active, no longer recruiting.
- 27 Sep 2022 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.